Sustained virological response to pegylated interferon and ribavirin is maintained during long‐term follow‐up of chronic hepatitis C patients

Abstract

SUMMARY BackgroundThere are few data in the literature regarding the long-term virological follow-up of chronic hepatitis C patients who obtain sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin therapy.

Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Naïve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3

“…Patients who achieve a sustained virological response (SVR) are considered cured in more than 99% of the cases according to long-term follow-up studies [6,7]. In pivotal clinical studies, an SVR was achieved in 41-52% of genotype 1 patients and in 73-82% of genotypes 2 and 3 patients treated with a SOC treatment [8,9,10].…”

Outcomes After Lung Transplantation and Practices of Lung Transplant Programs in the United States Regarding Hepatitis C Seropositive Recipients

“…HCV-seropositive individuals who are persistently HCV RNA negative have a false-positive anti-HCV antibody test result or have cleared infection spontaneously, or been successfully treated with anti-viral therapy. These patients are invariably HCV RNA negative in their liver tissue as well (20,21). Unfortunately, our study does not clarify the safety of performing lung transplantation on HCV RNA positive patients.…”

Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

“…Immunocompetent patients seem to lose SVR in 0-9% of cases, especially if they are treated with standard non-pegylated IFN alone and in the presence of advanced fibrosis or cirrhosis [19][20][21][22][23][24]. Notably, HCV reinfection due to ongoing risk-taking behaviours is still possible after SVR has been achieved [25], and surveillance for early HCC diagnosis should be maintained, at least in patients with established cirrhosis [20,21,[26][27][28][29][30].…”